The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer
Misako Nagasaka(University of California, Irvine), Stephen V. Liu(Georgetown University), Hossein Borghaei(Fox Chase Cancer Center), Luis E. Raez(Florida International University), Vijendra K. Singh(Wayne State University), Hirva Mamdani(Wayne State University), Rebecca Feldman(Caris Life Sciences (United States)), W. Michael Korn(Itasca Community College), Alexander I. Spira(Virginia Cancer Specialists), Sachin Gopalkrishna Pai(USA Mitchell Cancer Institute), Matthew J. Oberley(Caris Life Sciences (United States)), Edward S. Kim(The University of Texas MD Anderson Cancer Center), Yasmine Baca(Caris Life Sciences (United States)), Joanne Xiu(Caris Life Sciences (United States)), Dipesh Uprety(The Barbara Ann Karmanos Cancer Institute), Chukwuemeka Ikpeazu(Sylvester Comprehensive Cancer Center), Chul Kim(Georgetown University), Gerold Bepler(Moffitt Cancer Center), Antoinette J. Wozniak(Wayne State University), Ammar Sukari(The Barbara Ann Karmanos Cancer Institute)
Cited by 30
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k